Abstract | OBJECTIVE: METHODS: The Japanese Gynecologic Oncology Group (JGOG) study JGOG1066 enrolled patients with FIGO stages III-IVA uterine cervical cancer who had no para-aortic lymphadenopathy (>10 mm) assessed by CT. Patients received definitive radiotherapy (RT) consisting of external beam whole pelvic RT and HDR-ICBT. The cumulative linear quadratic equivalent dose (EQD2) was 62-65 Gy prescribed at point A. Cisplatin 40 mg/m(2) weekly was administered concurrently with RT for 5 courses. RESULTS: Of the 72 patients registered, 71 were eligible. With a median follow-up of 28 months, the 2-year progression-free survival rate and pelvic disease progression-free rate were 66% (95% CI, 54% to 76%) and 73% (95% CI, 61% to 82%), respectively. Progression-free survival decreased significantly with increased central tumor size (P=0.036). The 2-year cumulative late complication rates were 24% for all grades, 9% for grade 1, 12% for grade 2, 3% for grade 3, and 0 for grades 4/5. CONCLUSIONS: The JGOG1066 demonstrated that CCRT using HDR-ICBT with a low cumulative RT dose schedule achieved comparable outcome as those achieved with global dose schedules (EQD2=85 Gy) with a lower incidence of late toxicity for locally advanced uterine cervical cancer in a Japanese population.
|
Authors | Takafumi Toita, Ryo Kitagawa, Tetsutaro Hamano, Kenji Umayahara, Yasuyuki Hirashima, Yoichi Aoki, Masahiko Oguchi, Mikio Mikami, Ken Takizawa, Cervical Cancer (Vulva Cancer) Committee of Japanese Gynecologic Oncology Group (JGOG) |
Journal | Gynecologic oncology
(Gynecol Oncol)
Vol. 126
Issue 2
Pg. 211-6
(Aug 2012)
ISSN: 1095-6859 [Electronic] United States |
PMID | 22555110
(Publication Type: Clinical Trial, Phase II, Journal Article, Multicenter Study, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2012 Elsevier Inc. All rights reserved. |
Chemical References |
- Antineoplastic Agents
- Cisplatin
|
Topics |
- Adult
- Aged
- Antineoplastic Agents
(administration & dosage, adverse effects)
- Brachytherapy
(adverse effects, methods)
- Chemoradiotherapy
(adverse effects, methods)
- Cisplatin
(administration & dosage, adverse effects)
- Disease-Free Survival
- Dose Fractionation, Radiation
- Drug Administration Schedule
- Female
- Humans
- Middle Aged
- Prospective Studies
- Radiotherapy Dosage
- Treatment Outcome
- Uterine Cervical Neoplasms
(drug therapy, pathology, radiotherapy)
|